RT Journal Article
SR Electronic
T1 Environmental and genetic predictors of human cardiovascular ageing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.03.22280042
DO 10.1101/2022.10.03.22280042
A1 Shah, Mit
A1 Inácio, Marco H. de A.
A1 Lu, Chang
A1 Schiratti, Pierre-Raphaël
A1 Zheng, Sean L.
A1 Clement, Adam
A1 Bai, Wenjia
A1 King, Andrew P.
A1 Ware, James S.
A1 Wilkins, Martin R.
A1 Mielke, Johanna
A1 Elci, Eren
A1 Kryukov, Ivan
A1 McGurk, Kathryn A.
A1 Bender, Christian
A1 Freitag, Daniel F.
A1 O’Regan, Declan P.
YR 2022
UL http://medrxiv.org/content/early/2022/10/04/2022.10.03.22280042.abstract
AB Cardiovascular ageing is a process that begins early in life and leads to a progressive change in structure and decline in function due to accumulated damage across diverse cell types, tissues and organs contributing to multi-morbidity. Damaging biophysical, metabolic and immunological factors exceed endogenous repair mechanisms resulting in a pro-fibrotic state, cellular senescence and end-organ damage, however the genetic architecture of cardiovascular ageing is not known. Here we used machine learning approaches to quantify cardiovascular age from image-derived traits of vascular function, cardiac motion and myocardial fibrosis, as well as conduction traits from electrocardiograms, in 39,559 participants of UK Biobank. Cardiovascular ageing was found to be significantly associated with common or rare variants in genes regulating sarcomere homeostasis, myocardial immunomodulation, and tissue responses to biophysical stress. Ageing is accelerated by cardiometabolic risk factors and we also identified prescribed medications that were potential modifiers of ageing. Through large-scale modelling of ageing across multiple traits our results reveal insights into the mechanisms driving premature cardiovascular ageing and reveal potential molecular targets to attenuate age-related processes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by Bayer AG; Medical Research Council (MC\_UP\_1605/13); National Institute for Health Research (NIHR) Imperial College Biomedical Research Centre; and the British Heart Foundation (RG/19/6/34387, RE/18/4/34215).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent for participation in the study, which was approved by the National Research Ethics Service (11/NW/0382) in the UK.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analysis code is freely available on GitHub (https://github.com/ImperialCollegeLondon/cardiovascular_ageing). All raw and derived data in this study are available from UK Biobank (http://www.ukbiobank.ac.uk).